Resof Tablet + hepcfix 60 mg Tablet

Resof Tablet + Hepcfix 60 mg Tablet is a highly effective direct-acting antiviral (DAA) combination therapy designed for the treatment of chronic Hepatitis C Virus (HCV) infection. This powerful regimen combines Resof Tablet (Sofosbuvir 400 mg) with Hepcfix 60 mg Tablet (Daclatasvir 60 mg) to provide a dual-action approach that effectively inhibits viral replication and helps eliminate the Hepatitis C virus from the body. The combination has become a preferred treatment option worldwide because of its outstanding cure rates, excellent safety profile, convenient once-daily oral dosing, and ability to significantly reduce the risk of serious liver complications.

Resof Tablet contains Sofosbuvir 400 mg, a nucleotide analog NS5B polymerase inhibitor that blocks the enzyme responsible for viral RNA replication. By preventing the Hepatitis C virus from reproducing, Sofosbuvir rapidly reduces the viral load and limits further infection of healthy liver cells. Hepcfix 60 mg Tablet contains Daclatasvir 60 mg, an NS5A inhibitor that interferes with viral replication and assembly by targeting an essential viral protein. The combination of these two advanced antiviral medicines attacks the virus through different mechanisms, making treatment more effective while reducing the likelihood of antiviral resistance.

This combination therapy is commonly prescribed for adults diagnosed with chronic Hepatitis C Genotypes 1, 2, 3, and 4, depending on the patient's clinical condition, liver function, and physician's recommendation. Treatment is generally administered for 12 weeks, although some patients with advanced liver disease, compensated cirrhosis, or previous treatment failure may require therapy for 24 weeks. Numerous clinical studies have demonstrated sustained virologic response (SVR) rates exceeding 95%, indicating that the virus becomes undetectable after successful completion of therapy in the majority of patients.

One of the greatest advantages of Resof and Hepcfix therapy is its simple oral administration. Patients typically take one Resof 400 mg Tablet and one Hepcfix 60 mg Tablet once daily, with or without food, preferably at the same time every day. Maintaining a regular dosing schedule helps ensure stable blood concentrations of the medicines and maximizes antiviral effectiveness. Patients should complete the full prescribed course without interruption, even if they begin feeling better during treatment, as discontinuing therapy prematurely may reduce treatment success and increase the risk of viral relapse.

Compared with older interferon-based Hepatitis C treatments, this combination offers a much more favorable safety profile and is generally well tolerated by most patients. Common side effects are usually mild and may include headache, fatigue, nausea, dizziness, weakness, insomnia, and mild digestive discomfort. These symptoms often improve as treatment progresses and rarely require discontinuation of therapy. Serious adverse reactions are uncommon when the medication is taken under proper medical supervision. Healthcare professionals may recommend routine blood tests and liver function monitoring during treatment to evaluate therapeutic response and ensure patient safety.

Patients should inform their physician before starting therapy if they have a history of liver disease, kidney impairment, hepatitis B infection, HIV infection, pregnancy, breastfeeding, or any other significant medical condition. It is also important to disclose all prescription medicines, over-the-counter medications, vitamins, and herbal supplements being used, as certain drug interactions may affect the safety or effectiveness of Sofosbuvir and Daclatasvir. Alcohol consumption should be avoided during treatment because it can further damage the liver and reduce the benefits of antiviral therapy.

Successful treatment with Resof Tablet and Hepcfix 60 mg Tablet not only eliminates the Hepatitis C virus but also helps prevent serious long-term complications such as liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Achieving sustained virologic response significantly improves liver health, reduces disease progression, and enhances the patient's overall quality of life. Early diagnosis and prompt initiation of antiviral therapy remain essential for achieving the best possible clinical outcomes.

Resof Tablet and Hepcfix 60 mg Tablet should be stored in their original packaging in a cool, dry place away from direct sunlight, moisture, and excessive heat. The medicines should remain out of reach of children and should not be used after their expiration date. Proper storage helps preserve the quality, stability, and therapeutic effectiveness of the medication throughout its shelf life.

At Ayurmed Medicose, we are committed to supplying authentic, high-quality antiviral medicines that meet stringent international pharmaceutical standards. We provide genuine Resof Tablets and Hepcfix 60 mg Tablets sourced from trusted manufacturers, ensuring premium product quality, secure packaging, competitive pricing, and reliable worldwide delivery. Our dedication to product authenticity, customer satisfaction, and ethical pharmaceutical distribution has made Ayurmed Medicose a trusted partner for hospitals, pharmacies, healthcare professionals, wholesalers, and international buyers seeking dependable Hepatitis C treatment solutions. With a strong focus on quality assurance and professional service, we continue to support improved healthcare outcomes and provide reliable pharmaceutical products to customers across global markets.